Ubiquigent is a specialized company focused on enabling and supporting drug discovery through the modulation and exploitation of the ubiquitin system. The company operates in the biotechnology and pharmaceutical sectors, providing services and products that facilitate the development of novel compounds targeting protein degradation pathways. Ubiquigent's core offerings include chemistry and biology platforms that allow for the design and development of new compounds, as well as access to these platforms for compound evaluation, target validation, and target engagement studies. The company primarily serves pharmaceutical companies, biotech firms, and academic research institutions. Ubiquigent generates revenue through strategic partnerships, collaborative drug discovery projects, and the provision of specialized research tools and screening platforms. The business model is built on long-term collaborations and service agreements, ensuring a steady stream of income from both product sales and consultancy services.

Keywords: protein degradation, drug discovery, ubiquitin system, novel compounds, strategic partnerships, chemistry platforms, biology platforms, target validation, compound evaluation, biotech.